Imugene Ltd
ASX:IMU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jiangxi Sanxin Medtec Co Ltd
SZSE:300453
|
CN |
Imugene Ltd
Cash from Operating Activities
Imugene Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Imugene Ltd
ASX:IMU
|
Cash from Operating Activities
-AU$62.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-42%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Operating Activities
-$59.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Operating Activities
$3.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash from Operating Activities
-AU$7.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Operating Activities
-AU$17.3m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Operating Activities
-AU$65.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-58%
|
|
Imugene Ltd
Glance View
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
See Also
What is Imugene Ltd's Cash from Operating Activities?
Cash from Operating Activities
-62.9m
AUD
Based on the financial report for Dec 31, 2025, Imugene Ltd's Cash from Operating Activities amounts to -62.9m AUD.
What is Imugene Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-42%
Over the last year, the Cash from Operating Activities growth was 55%. The average annual Cash from Operating Activities growth rates for Imugene Ltd have been -15% over the past three years , -42% over the past five years , and -42% over the past ten years .
